Clinical Trials Logo

Clinical Trial Summary

The essential anesthesia requirements for FESS include airway management, considerations for facilitating surgical access, provision of a clear and still surgical field for precision surgery, assuring quick and non-stimulating emergence from anesthesia, and fast-tracking patients for discharge. Postoperative agitation, although short-lived, is potentially harmful to both patients and recovery room staff, it has a potential for self-injury by removing intravenous catheters, tubing, oxygen masks and nasal packs. Furthermore, very agitated patients can pose an immediate danger to operating theatre staff.


Clinical Trial Description

Lidocaine is an amino amide-type short-acting local anesthetic (LA). It has a short half-life, and a favorable safety profile, and is therefore the LA of choice for continuous IV administration, it has analgesic, and anti-inflammatory effects that are induced by reduction of cytokines production through inhibition of neutrophil activation, and the analgesia may persist even after plasma concentration reduction. It can blunt the pressor response to endotracheal intubation also systemic lidocaine was effective in producing controlled hypotension. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04472689
Study type Interventional
Source Alexandria University
Contact Rehab A. Abd Elaziz, Ass. Prof.
Phone 01001073703
Email trcium2002@yahoo.com
Status Recruiting
Phase N/A
Start date July 1, 2020
Completion date October 20, 2020

See also
  Status Clinical Trial Phase
Completed NCT02270125 - Nanoparticles in Nasal Mucosa